Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, $62 PT on Humana

Related HUM
Humana Expands Value-Based Arrangement With MemorialCare Medical Group And MemorialCare Health System To Include Greater Newport Physicians And Edinger Medical Group
Humana And MDX Hawai'i Partner To Launch Accountable Care Agreement In Hawai'i
Humana Sees Exchange Customer Growth in '14 (Fox Business)

In a report published Wednesday, Goldman Sachs Group reiterated its Sell rating and $62.00 price target on Humana (NYSE: HUM).

Goldman Sachs noted, “The focus of the investor day was the transition to provider-integrated care (owned and risk-contracted) that offers lower cost / higher quality outcomes versus traditional fee-for-service. With Medicare Advantage (MA) driving the majority of revenue and earnings, we think integrated care is the right model to better position Humana for tighter MA reimbursement as health reform rolls through and also the right model to strengthen Humana's role in easing the national Medicare cost crisis in the years ahead.”

Humana closed on Tuesday at $68.29.

Latest Ratings for HUM

DateFirmActionFromTo
Sep 2014CitigroupMaintainsSell
Sep 2014JP MorganMaintainsOverweight
Aug 2014Raymond JamesMaintainsOutperform

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

Around the Web, We're Loving...

Get Benzinga's Newsletters